SCHEMBL30295809

SCHEMBL30295809

CN1CCN(c2ncnc3c2c(-c2cccc(Cl)c2)cn3COCC[Si](C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.46
▸ MAPT P10636 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ HTT P42858 1/20 0.45
▸ TAAR1 Q96RJ0 1/20 0.44
▸ TP53 P04637 2/20 0.43
▸ STK4 Q13043 6/20 0.43
▸ STK3 Q13188 6/20 0.43
▸ LRRK2 Q5S007 5/20 0.43
▸ PDE10A Q9Y233 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30295816 0.89 LMNA (0.47) LMNAMAPTMEN1KMT2AHTT
SCHEMBL30295703 0.88 STK4 (0.45) LMNAMAPTMEN1KMT2ATP53
SCHEMBL30295902 0.87 STK4 (0.44) LMNAMAPTMEN1KMT2ATP53
SCHEMBL30295700 0.85 SRC (0.42) LMNAKMT2ATP53STK4STK3
SCHEMBL30296050 0.84 LRRK2 (0.62) LMNAMAPTMEN1KMT2ATP53
SCHEMBL31301627 0.83 STK4 (0.46) LMNAMAPTTP53STK4STK3
SCHEMBL30295781 0.83 STK4 (0.46) LMNAMAPTMEN1KMT2ATP53
SCHEMBL30295729 0.80 STK4 (0.43) LMNATP53STK4STK3LRRK2
SCHEMBL31301618 0.79 RIPK2 (0.39) LMNATP53STK4STK3LRRK2
SCHEMBL15401848 0.78 LRRK2 (0.55) LMNAMAPTMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-02-13 — — US disclosed
WO-2023055731-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2023-04-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF STK3, STK4, STK36 LMNA 2993/4885MAPT 915/4885MEN1 3676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback